- GPC Biotech AG
- Medigene AG
- Sygnis AG
- Evotec AG
- DeveloGen AG
- HepaVec AG
- Oxford Asymmetry International PLC
- MediGene Inc.
- Takeda Oncology
- Morphochem AG
- Merckle GMBH
- Technilab Pharma Inc.
- MorphoSys AG
- Cambridge Antibody Technology Group PLC
- Oxford GlycoSciences PLC
- Cantab Biopharmaceuticals Ltd.
- Immunex Corp.
- Genzyme Corp.
- Genzyme General
- Medarex Inc.
- Boehringer Ingelheim Fremont Inc.
- GPC AG raises $96mm in IPO
- MediGene gets $102.5mm with IPO
- Lion Bioscience raises $209mm in IPO
- German biotechs DeveloGen and HepaVec are merging
- Evotec acquires Oxford Asymmetry
- MediGene acquires NeuroVir Therapeutics in stock swap
- GPC AG to buy Mitotix in all-stock deal
- Morphochem acquires Small Molecule Therapeutics
- Merckle acquires Technilab Pharma
- Evotec BioSystems acquires Genion for $2.4mm in stock
- CAT, Human Genome Sciences in $67mm antibody collaboration
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.